GSK3B and neoplasm: Specifically, the glycogen synthase kinase-3 beta (GSK-3β) has been recognized as anti-inflammatory and anti-tumor therapeutic target for steroidal saponins compounds derived from TTM (Lee et al., 2007; Li et al., 2014; Fang et al., 2016; Mou et al., 2017).